Caribou Biosciences

Caribou Biosciences

Biotechnology Research

Berkeley, CA 34,968 followers

Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases

About us

Caribou Biosciences is a leading clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our next-generation genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. We believe the future of cell therapy is off-the-shelf, and we are advancing our pipeline of off-the-shelf, or allogeneic, cell therapies from our CAR-T cell therapy platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases.

Website
http://cariboubio.com
Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Berkeley, CA
Type
Public Company
Founded
2012
Specialties
Next-generation CRISPR genome editing, allogeneic CAR-T cell therapies, oncology, and autoimmune

Locations

Employees at Caribou Biosciences

Updates

Similar pages

Browse jobs

Funding

Caribou Biosciences 9 total rounds

Last Round

Post IPO equity

US$ 125.0M

See more info on crunchbase